Evidence map›Paper›PMID 24080384›Full record

ArticleThe American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry2014

Pre-clinical cognitive phenotypes for Alzheimer disease: a latent profile approach.

Kathleen M Hayden, Maragatha Kuchibhatla, Heather R Romero, Brenda L Plassman, James R Burke, Jeffrey N Browndyke, Kathleen A Welsh-Bohmer

Abstract read
In one paragraph

Article in The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. The Cognitive Connectome in Healthy Aging.Frontiers in aging neuroscience · 2021
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kathleen M HaydenJoseph and Kathleen Bryan ADRC, Duke University Medical Center, Durham, NC. Electronic address: khayden@duke.edu.
Maragatha KuchibhatlaDepartment of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC.
Heather R RomeroJoseph and Kathleen Bryan ADRC, Duke University Medical Center, Durham, NC.
Brenda L PlassmanJoseph and Kathleen Bryan ADRC, Duke University Medical Center, Durham, NC.
James R BurkeJoseph and Kathleen Bryan ADRC, Duke University Medical Center, Durham, NC.
Jeffrey N BrowndykeJoseph and Kathleen Bryan ADRC, Duke University Medical Center, Durham, NC.
Kathleen A Welsh-BohmerJoseph and Kathleen Bryan ADRC, Duke University Medical Center, Durham, NC.
Duke University · USDuke Medical Center · US

Funding

NATIONAL ALZHEIMERS COORDINATING CENTER (NACC)U01AG016976 · NIA · UNIVERSITY OF WASHINGTON · PI KUKULL, WALTER ANTHONY · 1999 to 2020
$72.8M
NEUROPATHOLOGY COREP30AG028377 · NIA · DUKE UNIVERSITY · PI WELSH-BOHMER, KATHLEEN ANNE · 2006 to 2011
$9.6M
Cognitive Endophenotypes for Genetic Studies of Alzheimer's DiseaseK01AG029336 · NIA · DUKE UNIVERSITY · PI HAYDEN, KATHLEEN M · 2007 to 2011
$588k
NIA NIH HHS K01 AG029336NIA NIH HHS K01-AG029336NIA NIH HHS P30 AG028377NIA NIH HHS P30-AG028377NIA NIH HHS U01 AG016976NIA NIH HHS U01-AG016976
6 · The paper itself

Abstract

backgroundCognitive profiles for pre-clinical Alzheimer disease (AD) can be used to identify groups of individuals at risk for disease and better characterize pre-clinical disease. Profiles or patterns of performance as pre-clinical phenotypes may be more useful than individual test scores or measures of global decline.

objectiveTo evaluate patterns of cognitive performance in cognitively normal individuals to derive latent profiles associated with later onset of disease using a combination of factor analysis and latent profile analysis.

methodsThe National Alzheimer Coordinating Centers collect data, including a battery of neuropsychological tests, from participants at 29 National Institute on Aging-funded Alzheimer Disease Centers across the United States. Prior factor analyses of this battery demonstrated a four-factor structure comprising memory, attention, language, and executive function. Factor scores from these analyses were used in a latent profile approach to characterize cognition among a group of cognitively normal participants (N = 3,911). Associations between latent profiles and disease outcomes an average of 3 years later were evaluated with multinomial regression models. Similar analyses were used to determine predictors of profile membership.

resultsFour groups were identified; each with distinct characteristics and significantly associated with later disease outcomes. Two groups were significantly associated with development of cognitive impairment. In post hoc analyses, both the Trail Making Test Part B, and a contrast score (Delayed Recall - Trails B), significantly predicted group membership and later cognitive impairment.

conclusionsLatent profile analysis is a useful method to evaluate patterns of cognition in large samples for the identification of preclinical AD phenotypes; comparable results, however, can be achieved with very sensitive tests and contrast scores.

Indexed as

CognitionAgedAged, 80 and overAlzheimer DiseaseAttentionCognitive DysfunctionExecutive FunctionFactor Analysis, StatisticalFemaleHumansLanguageMaleMemoryNeuropsychological TestsPhenotypeProdromal Symptomsfactor analysisLatent profile analysislongitudinal studyneuropsychological test

Identifiers

PMID24080384
PMCPMC3968245
OpenAlexW2052556358

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.